| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
VRT-18858
ID: ALA437105
Max Phase: Unknown
Molecular Formula: C24H25N5O7
Molecular Weight: 495.49
Molecule Type: Protein
Associated Items:
Representations
Synonyms (4): Vrt-18858 | RU-38384 | RU38384 | VRT18858
Synonyms from Alternative Forms(4):
Canonical SMILES: O=C[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3nccc4ccccc34)C(=O)N12
Standard InChI: InChI=1S/C24H25N5O7/c30-13-15(12-20(32)33)26-22(34)18-6-3-11-28-19(31)8-7-17(24(36)29(18)28)27-23(35)21-16-5-2-1-4-14(16)9-10-25-21/h1-2,4-5,9-10,13,15,17-18H,3,6-8,11-12H2,(H,26,34)(H,27,35)(H,32,33)/t15-,17-,18-/m0/s1
Standard InChI Key: CUVNEENHHCPUBW-SZMVWBNQSA-N
Associated Targets(Human)
CASP1 Tchem Caspase-1 (6235 Activities)
PBMC (10003 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Casp1 Caspase-1 (361 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mus musculus (284745 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: Yes | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 495.49 | Molecular Weight (Monoisotopic): 495.1754 | AlogP: 0.02 | #Rotatable Bonds: 7 |
| Polar Surface Area: 166.08 | Molecular Species: ACID | HBA: 7 | HBD: 3 |
| #RO5 Violations: 0 | HBA (Lipinski): 12 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 3.81 | CX Basic pKa: 2.47 | CX LogP: -1.24 | CX LogD: -4.33 |
| Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.45 | Np Likeness Score: -0.14 |
References
| 1. Wang Y, O'Neil SV, Wos JA, Oppong KA, Laufersweiler MC, Soper DL, Ellis CD, Baize MW, Fancher AN, Lu W, Suchanek MK, Wang RL, Schwecke WP, Cruze CA, Buchalova M, Belkin M, De B, Demuth TP.. (2007) Synthesis and evaluation of unsaturated caprolactams as interleukin-1beta converting enzyme (ICE) inhibitors., 15 (3): [PMID:17127070] [10.1016/j.bmc.2006.11.011] |
| 2. Galatsis P, Caprathe B, Gilmore J, Thomas A, Linn K, Sheehan S, Harter W, Kostlan C, Lunney E, Stankovic C, Rubin J, Brady K, Allen H, Talanian R.. (2010) Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1)., 20 (17): [PMID:20656488] [10.1016/j.bmcl.2010.07.004] |
| 3. Baldwin AG, Brough D, Freeman S.. (2016) Inhibiting the Inflammasome: A Chemical Perspective., 59 (5): [PMID:26422006] [10.1021/acs.jmedchem.5b01091] |
| 4. Unpublished dataset, |
| 5. Ulgheri F, Spanu P, Deligia F, Loriga G, Fuggetta MP, de Haan I, Chandgudge A, Groves M, Domling A.. (2022) Design, synthesis and biological evaluation of 1,5-disubstituted α-amino tetrazole derivatives as non-covalent inflammasome-caspase-1 complex inhibitors with potential application against immune and inflammatory disorders., 229 [PMID:34823899] [10.1016/j.ejmech.2021.114002] |
Source
Source(2):